AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Positive results reported from phase II study of lidocaine vaginal gel.
2004 MAR 4 - (NewsRx.com & NewsRx.net) -- Columbia Laboratories (COB) announced the successful completion of a trial evaluating the effect of Columbia's lidocaine bioadhesive vaginal gel on uterine contractions and pain.
Trial results showed that Columbia's lidocaine gel reduced the frequency of uterine contractions, as well as the intensity and frequency of uterine pain.
This study was designed to evaluate lidocaine formulated with Columbia's proprietary bioadhesive vaginal gel versus placebo. The single-blind, parallel-group, placebo-controlled trial was conducted in 24 subjects with a history of dysmenorrhea. Subjects were evaluated following vasopressin-induced cramping in the late luteal phase of the menstrual cycle, near menses.
Subjects treated with lidocaine vaginal gel experienced a numerical trend showing an overall reduction in the intensity of intra-uterine pressure, intensity of pain and frequency of pain. The data demonstrated statistical significance (p-value
The study also ...
- Columbia Laboratories Completes Lidocaine Vaginal Gel Pharmacokinetics Study;...
- Press release article from: Business Wire September 8, 2005 700+ words
...announced the successful completion of its lidocaine vaginal gel pharmacokinetics study. Lidocaine vaginal gel is under development by the Company...in a pilot study of the Company's lidocaine vaginal gel were published in the April 2005 supplement...
- Abstract on Columbia Laboratories' Lidocaine Vaginal Gel Published in ACOG's...
- Press release article from: Business Wire April 4, 2005 700+ words
...placebo-controlled study of lidocaine vaginal gel, the Company's investigational...concluded that pretreatment with lidocaine vaginal gel reduces intrauterine pressure...2005 to further evaluate lidocaine vaginal gel in the treatment of dysmenorrhea...
- Columbia Laboratories Reports Positive Results From Phase II Study of Lidocaine...
- Press release article from: PR Newswire February 5, 2004 700+ words
...menses. Subjects treated with lidocaine vaginal gel experienced a numerical trend...lt; 0.050) in favor of lidocaine vaginal gel at all time points after...lt; 0.050) favoring lidocaine vaginal gel for frequency of contractions...
- Positive results reported from phase II study of lidocaine vaginal gel.
- Newspaper article from: Drug Week March 5, 2004 700+ words
...menses. Subjects treated with lidocaine vaginal gel experienced a numerical trend...lt; 0.050) in favor of lidocaine vaginal gel at all time points after...lt;0.050) favoring lidocaine vaginal gel for frequency of contractions...
- Upsher-Smith Launches New Vandazole(TM) (Metronidazole Vaginal Gel, 0.75%) for...
- Press release article from: PR Newswire October 11, 2005 700+ words
...new Vandazole(TM) (metronidazole vaginal gel, 0.75%) for treatment of bacterial...vaginal applicators, Vandazole(TM) Vaginal Gel is the first vaginal, economical alternative...bacterial vaginosis in the metronidazole vaginal gel market. Vandazole(TM) Vaginal Gel...
- Phase III trial with 1% C31G vaginal gel initiated.
- Newspaper article from: Clinical Trials Week June 14, 2004 700+ words
...of its lead drug candidate, 1% C31G vaginal gel, for the reduction of sexual transmission...to evaluate the effects of 1% C31G vaginal gel on the prevention of transmission of...in the near future. One percent C31G vaginal gel is in development for contraception...
- Biosyn, Inc. Initiates Phase 3 Pivotal Clinical Trial with 1% C31G Vaginal Gel...
- Press release article from: PR Newswire May 20, 2004 700+ words
...of its lead drug candidate, 1% C31G vaginal gel, for the reduction of sexual transmission...to evaluate the effects of 1% C31G vaginal gel on the prevention of transmission of...Nigeria, in the near future. 1% C31G vaginal gel is in development for contraception...
- FDA Grants Fast Track Designation for 1.0% C31G Vaginal Gel for the Reduction...
- Press release article from: PR Newswire November 17, 2003 700+ words
...development program of 1.0% C31G vaginal gel for the reduction of HIV transmission...help accelerate our development of C31G vaginal gel." Fast track programs are designed...lead product candidate, 1.0% C31G vaginal gel is entering Phase III clinical trials...
Source: HighBeam Research, Positive results reported from phase II study of lidocaine vaginal...